Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2012

Open Access 01-12-2012 | Research

Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey

Authors: Puja P Khanna, George Nuki, Thomas Bardin, Anne-Kathrin Tausche, Anna Forsythe, Amir Goren, Jeffrey Vietri, Dinesh Khanna

Published in: Health and Quality of Life Outcomes | Issue 1/2012

Login to get access

Abstract

Background

The prevalence of gout is increasing, and most research on the associated burden has focused on serum urate (sUA) levels. The present study quantifies the impact of the presence of tophi and frequency of acute gout attacks on health-related quality of life (HRQOL), productivity, and healthcare resource utilization.

Methods

Patients with self-reported gout (n = 620; 338 in US and 282 across France, Germany, and UK) were contacted based on inclusion in the 2010 US and EU National Health and Wellness Surveys (Kantar Health) and the Lightspeed Research ailment panel. Respondents were categorized into mutually-exclusive groups based on number of gout flares experienced in the past 12 months (0/don’t recall, 1–2, 3, 4–5, 6+), current presence of tophi (none, 1+, or not sure), and sUA level awareness (yes, no). HRQOL (SF-12v2), healthcare provider visits in the last 6 months, and work productivity and activity impairment (WPAI) were compared across groups.

Results

Most patients were males, mean age of 61 years, who reported experiencing at least one acute gout flare in the past 12 months, and 12.3% (n = 76) reported presence of tophi. Among the 27.7% (n = 172) of patients who were aware of their sUA levels, higher sUA was associated with more flares and tophi. Decreased HRQOL was associated with more frequent flares and presence of tophi. In multivariable models predicting outcomes based on presence of tophi and number of flares, both flares (≥4) and tophi (≥1) were associated with HRQOL decrements on physical and mental component summary scores and health utilities (all p < 0.05), after adjustment for age, gender, and time since diagnosis. Flares were also associated with greater activity impairment.

Conclusions

Impairments associated with gout flares and presence of tophi, across patients in the US and EU, underscore the importance of effective management of this potentially curable condition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis & Rheumatism 2011, 63: 3136–3141. 10.1002/art.30520CrossRef Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis & Rheumatism 2011, 63: 3136–3141. 10.1002/art.30520CrossRef
2.
go back to reference Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008, 67: 960–966.PubMedCentralCrossRefPubMed Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008, 67: 960–966.PubMedCentralCrossRefPubMed
3.
go back to reference Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29: 2403–2406.PubMed Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29: 2403–2406.PubMed
4.
go back to reference Mikuls TR, Saag KG: New insights into gout epidemiology. Curr Opin Rheumatol 2006, 18: 199–203. 10.1097/01.bor.0000209435.89720.7cCrossRefPubMed Mikuls TR, Saag KG: New insights into gout epidemiology. Curr Opin Rheumatol 2006, 18: 199–203. 10.1097/01.bor.0000209435.89720.7cCrossRefPubMed
5.
go back to reference Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX: A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25: 1593–1617. 10.1016/S0149-2918(03)80158-3CrossRefPubMed Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX: A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003, 25: 1593–1617. 10.1016/S0149-2918(03)80158-3CrossRefPubMed
6.
go back to reference Tausche AK, Panzner I, Aust D, Wunderlich C: Disabling gout. Lancet 2010, 376: 1093. 10.1016/S0140-6736(10)60135-3CrossRefPubMed Tausche AK, Panzner I, Aust D, Wunderlich C: Disabling gout. Lancet 2010, 376: 1093. 10.1016/S0140-6736(10)60135-3CrossRefPubMed
7.
go back to reference Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin North Am 1990, 16: 539–550.PubMed Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin North Am 1990, 16: 539–550.PubMed
8.
go back to reference Tausche AK, Manger B, Muller-Ladner U, Schmidt B: Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia. Z Rheumatol 2012, 71: 224–230. 10.1007/s00393-011-0953-9CrossRefPubMed Tausche AK, Manger B, Muller-Ladner U, Schmidt B: Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia. Z Rheumatol 2012, 71: 224–230. 10.1007/s00393-011-0953-9CrossRefPubMed
9.
go back to reference Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65: 1312–1324. 10.1136/ard.2006.055269PubMedCentralCrossRefPubMed Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, et al.: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65: 1312–1324. 10.1136/ard.2006.055269PubMedCentralCrossRefPubMed
10.
go back to reference Perez-Ruiz F: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009, 48(Suppl 2):ii9-ii14. 10.1093/rheumatology/kep087CrossRef Perez-Ruiz F: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009, 48(Suppl 2):ii9-ii14. 10.1093/rheumatology/kep087CrossRef
11.
go back to reference Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12: 61–65. 10.1097/01.rhu.0000209882.50228.9fCrossRefPubMed Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12: 61–65. 10.1097/01.rhu.0000209882.50228.9fCrossRefPubMed
12.
go back to reference Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Care & Research 2004, 51: 321–325. 10.1002/art.20405CrossRef Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Care & Research 2004, 51: 321–325. 10.1002/art.20405CrossRef
13.
go back to reference Murshid WR, Moss TH, Ettles DF, Cummins BH: Tophaceous gout of the spine causing spinal cord compression: Short Report. Br J Neurosurg 1994, 8: 751–754. 10.3109/02688699409101193CrossRefPubMed Murshid WR, Moss TH, Ettles DF, Cummins BH: Tophaceous gout of the spine causing spinal cord compression: Short Report. Br J Neurosurg 1994, 8: 751–754. 10.3109/02688699409101193CrossRefPubMed
14.
go back to reference Akizuki S, Matsui T: Entrapment neuropathy caused by tophaceous gout. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand 1984, 9: 331–332.CrossRef Akizuki S, Matsui T: Entrapment neuropathy caused by tophaceous gout. The Journal of Hand Surgery: Journal of the British Society for Surgery of the Hand 1984, 9: 331–332.CrossRef
15.
go back to reference Magid SK, Gray GE, Anand A: Spinal cord compression by tophi in a patient with chronic polyarthritis: case report and literature review. Arthritis & Rheumatism 1981, 24: 1431–1434. 10.1002/art.1780241117CrossRef Magid SK, Gray GE, Anand A: Spinal cord compression by tophi in a patient with chronic polyarthritis: case report and literature review. Arthritis & Rheumatism 1981, 24: 1431–1434. 10.1002/art.1780241117CrossRef
16.
go back to reference Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR: The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009, 15: 3–7. 10.1097/RHU.0b013e3181945d2cCrossRefPubMed Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR: The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009, 15: 3–7. 10.1097/RHU.0b013e3181945d2cCrossRefPubMed
17.
go back to reference Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47: 356–360. 10.1002/art.10511CrossRefPubMed Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47: 356–360. 10.1002/art.10511CrossRefPubMed
18.
go back to reference Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z: Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. JAMA: The Journal of the American Medical Association 2011, 306: 711. 10.1001/jama.2011.1169CrossRefPubMed Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z: Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. JAMA: The Journal of the American Medical Association 2011, 306: 711. 10.1001/jama.2011.1169CrossRefPubMed
20.
go back to reference Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009, 48: 582–586.CrossRef Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009, 48: 582–586.CrossRef
21.
go back to reference Singh JA, Reddy SG, Kundukulam J: Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011, 23: 192–202.PubMedCentralPubMed Singh JA, Reddy SG, Kundukulam J: Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011, 23: 192–202.PubMedCentralPubMed
22.
go back to reference Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, Tsevat J: The disutility of chronic gout. Qual Life Res 2008, 17: 815–822. 10.1007/s11136-008-9355-0CrossRefPubMed Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, Tsevat J: The disutility of chronic gout. Qual Life Res 2008, 17: 815–822. 10.1007/s11136-008-9355-0CrossRefPubMed
23.
go back to reference Khanna PP, Perez-Ruiz F, Maranian P, Khanna D: Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011, 50: 740–745. 10.1093/rheumatology/keq346CrossRef Khanna PP, Perez-Ruiz F, Maranian P, Khanna D: Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011, 50: 740–745. 10.1093/rheumatology/keq346CrossRef
24.
go back to reference Singh JA, Strand V: Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008, 67: 1310–1316.CrossRefPubMed Singh JA, Strand V: Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008, 67: 1310–1316.CrossRefPubMed
25.
go back to reference DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W: Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010, 13: 709–718. 10.3111/13696998.2010.535576CrossRefPubMed DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W: Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010, 13: 709–718. 10.3111/13696998.2010.535576CrossRefPubMed
26.
go back to reference Bolge SC, Doan JF, Kannan H, Baran RW: Association of insomnia with quality of life, work productivity, and activity impairment. Quality of life Research 2009, 18: 415–422. 10.1007/s11136-009-9462-6CrossRefPubMed Bolge SC, Doan JF, Kannan H, Baran RW: Association of insomnia with quality of life, work productivity, and activity impairment. Quality of life Research 2009, 18: 415–422. 10.1007/s11136-009-9462-6CrossRefPubMed
27.
go back to reference Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12 Health Survey. Quality Metric, Lincoln, RI; 2002. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12 Health Survey. Quality Metric, Lincoln, RI; 2002.
28.
go back to reference Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Heal Econ 2002, 21: 271–292. 10.1016/S0167-6296(01)00130-8CrossRef Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-36. J Heal Econ 2002, 21: 271–292. 10.1016/S0167-6296(01)00130-8CrossRef
29.
go back to reference Hays RD, Morales LS: The RAND-36 measure of health-related quality of life. Ann Med 2001, 33: 350–357. 10.3109/07853890109002089CrossRefPubMed Hays RD, Morales LS: The RAND-36 measure of health-related quality of life. Ann Med 2001, 33: 350–357. 10.3109/07853890109002089CrossRefPubMed
30.
go back to reference Walters SJ, Brazier JE: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14: 1523–1532. 10.1007/s11136-004-7713-0CrossRefPubMed Walters SJ, Brazier JE: Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14: 1523–1532. 10.1007/s11136-004-7713-0CrossRefPubMed
31.
go back to reference Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4: 353–365. 10.2165/00019053-199304050-00006CrossRefPubMed Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4: 353–365. 10.2165/00019053-199304050-00006CrossRefPubMed
32.
go back to reference Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical care 2003, 41: 582.PubMed Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical care 2003, 41: 582.PubMed
33.
go back to reference Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M: Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther 2011. Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M: Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. Am J Ther 2011.
34.
go back to reference Roddy E, Zhang W, Doherty M: Is gout associated with reduced quality of life? A case–control study. Rheumatology (Oxford) 2007, 46: 1441–1444. 10.1093/rheumatology/kem150CrossRef Roddy E, Zhang W, Doherty M: Is gout associated with reduced quality of life? A case–control study. Rheumatology (Oxford) 2007, 46: 1441–1444. 10.1093/rheumatology/kem150CrossRef
35.
go back to reference Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, et al.: Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36: 1041–1048. 10.3899/jrheum.071229CrossRefPubMed Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, et al.: Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36: 1041–1048. 10.3899/jrheum.071229CrossRefPubMed
36.
go back to reference Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N: The economic burden of gout on an employed population. Curr Med Res Opin 2006, 22: 1381–1389. 10.1185/030079906X112606CrossRefPubMed Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N: The economic burden of gout on an employed population. Curr Med Res Opin 2006, 22: 1381–1389. 10.1185/030079906X112606CrossRefPubMed
37.
go back to reference Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, van Zanten SV: Gout in the elderly–a population health study. J Rheumatol 2009, 36: 822–830. 10.3899/jrheum.080768CrossRefPubMed Hanly JG, Skedgel C, Sketris I, Cooke C, Linehan T, Thompson K, van Zanten SV: Gout in the elderly–a population health study. J Rheumatol 2009, 36: 822–830. 10.3899/jrheum.080768CrossRefPubMed
38.
go back to reference Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, Kavanaugh A, Hirsch JD: Health care utilization in patients with gout. Semin Arthritis Rheum 2011, 40: 501–511. 10.1016/j.semarthrit.2010.07.001PubMedCentralCrossRefPubMed Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, Kavanaugh A, Hirsch JD: Health care utilization in patients with gout. Semin Arthritis Rheum 2011, 40: 501–511. 10.1016/j.semarthrit.2010.07.001PubMedCentralCrossRefPubMed
39.
go back to reference Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009, 36: 1032–1040. 10.3899/jrheum.080487CrossRefPubMed Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009, 36: 1032–1040. 10.3899/jrheum.080487CrossRefPubMed
40.
go back to reference Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N: The impact of gout on work absence and productivity. Value Health 2007, 10: 231–237. 10.1111/j.1524-4733.2007.00173.xCrossRefPubMed Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N: The impact of gout on work absence and productivity. Value Health 2007, 10: 231–237. 10.1111/j.1524-4733.2007.00173.xCrossRefPubMed
41.
go back to reference Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA: Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011, 14: 10–15. 10.3111/13696998.2010.540874CrossRefPubMed Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA: Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011, 14: 10–15. 10.3111/13696998.2010.540874CrossRefPubMed
42.
go back to reference Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350: 1093–1103. 10.1056/NEJMoa035700CrossRefPubMed Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350: 1093–1103. 10.1056/NEJMoa035700CrossRefPubMed
43.
go back to reference Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin N Am 1990, 16: 539. Roubenoff R: Gout and hyperuricemia. Rheum Dis Clin N Am 1990, 16: 539.
44.
go back to reference McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC: Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 2011, 38: 135–141. 10.3899/jrheum.100418PubMedCentralCrossRefPubMed McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC: Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol 2011, 38: 135–141. 10.3899/jrheum.100418PubMedCentralCrossRefPubMed
Metadata
Title
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey
Authors
Puja P Khanna
George Nuki
Thomas Bardin
Anne-Kathrin Tausche
Anna Forsythe
Amir Goren
Jeffrey Vietri
Dinesh Khanna
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2012
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-10-117

Other articles of this Issue 1/2012

Health and Quality of Life Outcomes 1/2012 Go to the issue